Optimizing management in autoimmune hepatitis with liver failure at initial presentation

Table 2 Outcomes of patients with autoimmune hepatitis and initial presentation with liver failure

Study	Villamil et al[22](n = 28)	Kessler et al[23](n = 10)	Miyake et al[24](n = 11)	Ichai et al[25](n = 16)	Verma et al[7](n = 20)
Treated with IS1	25	10	8	12	14
Responders to steroids	9 (36%) (alive)	4 (40%) (alive)	2 (25%) (alive)	1 (8.3%) (alive)	7 (50%) (alive)
Non responders	16	6	6	11	7
LT	11 (2 Died)	3	1	10 (1 Died)	1 (Died)
Listed for LT	-	1	-	-	1 (Died)
Died without LT	5	2	5	14	52
Not treated with IS1	3	-	33	4	6
Spontaneous survival	-	-	3	-	-
LT	1	-	-	3	5 (1 Died)
Listed for LT	-	-	-	-	-
Died	2	-	-	1	1
Overall underwent LT or listed for LT	12/28 (42.8%)	4/10 (40%)	1/11 (9%)	13/16 (81.2%)	7/20 (35%)
Overall mortality	9/28 (32.1%)	2/10 (20%)	5/11 (45.4%)	3/16 (18.7%)	9/20 (45%)

¹IS: Immunosuppression;

²Four died while being evaluated for liver transplantation, in 1 sepsis precluded liver transplantation evaluation;

³Treated with plasmapheresis and or stronger neo-minophagen;

⁴Not evaluated for LT due to sepsis; LT: Liver transplantation. Additional outcome data obtained by personal communication with authors.